BRIEF—Helsinn invests to safeguard the quality and authenticity of its products

Swiss cancer focussed drugmaker Helsinn today announced a 6million-euro (~$7 million) investment at its drug product supply center, Helsinn Birex Pharmaceuticals (HBP) in Dublin Ireland, as part of its ongoing commitment to ensuring high quality products, safeguarding its supply chain and in compliance with regulatory requirements worldwide.

Unauthorized distribution of adulterated or counterfeit products is high on the global regulatory agenda, and protecting the quality of its products during distribution is a key priority for Helsinn and its partners.

The investment is designed to safeguard Helsinn’s supply of quality products that comply with the stringent quality standards for our markets, and that are safe for patient use.

The investments provide HBP with the capability to apply unique serial numbers and tamper evidence features, which meet requirements of the US Drug Quality and Security Act (DQSA), the EU Falsified Medicines Directive (FMD), and other relevant local requirements in markets where Helsinn cancer care products are sold.

The enhancements to products across all markets in which Helsinn is active demonstrates Helsinn’s clear commitment to comply with regulatory requirements while providing partners and the patients who use the products with the assurance that the products supplied are authentic and fit for purpose.